Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Immunomet Therapeutics Inc.

Headquarters: Houston, TX, United States of America
Year Founded: 2015
Status: Private

BioCentury | Mar 25, 2021
Management Tracks

Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Bart Filius to president from CFO while remaining COO. CEO Onno van de Stolpe will be responsible for oversight of R&D activities. Caroline
BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

BioCentury | Feb 13, 2018
Company News

Management tracks: Cytokinetics, Surface Oncology

BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

BioCentury | Sep 26, 2017
Distillery Therapeutics

Cancer

BioCentury | Jun 16, 2017
Emerging Company Profile

Metabolic regulation

ImmunoMet aims to block metabolism in cancer and immunosuppressive cells
BioCentury | Mar 9, 2017
Financial News

ImmunoMet Therapeutics completes venture financing

Items per page:
1 - 9 of 9